Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400804 | 0.89 | PDE5A (0.68) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL400090 | 0.89 | PDE5A (0.78) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL403686 | 0.88 | PDE5A (0.71) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL404136 | 0.88 | PDE5A (0.77) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL403830 | 0.88 | PDE5A (0.67) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL400983 | 0.87 | PDE5A (0.76) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL406051 | 0.87 | PDE5A (0.63) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL403490 | 0.87 | PDE5A (0.65) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL403375 | 0.86 | PDE5A (0.68) | PDE5AKDM4ERECQLKMT2APOLB | |
| SCHEMBL405142 | 0.86 | PDE5A (0.65) | PDE5AKDM4ERECQLKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050739-B1 | QUINAZOLINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2016-07-06 | — | — | EP | disclosed |
| CN-101501007-B | Quinazoline derivative | ASKA PARMACEUTICAL CO LTD | 2014-01-29 | — | — | CN | disclosed |
| US-8101624-B2 | Quinazoline derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | ASKA PHARMACEUTICAL CO., LTD. | 2009-12-24 | — | — | US | disclosed |
| EP-2123301-A1 | THERAPEUTIC AGENT FOR URINARY TRACT DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| CN-101557826-A | Therapeutic agent for urinary tract disease | ASKA PHARM CO LTD (JP) | 2009-10-14 | — | — | CN | disclosed |
| CN-101501007-A | Quinazoline derivative | ASKA PARMACEUTICAL CO LTD (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2050739-A1 | QUINAZOLINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113484-A1 | TREATING AGENT OF UROPATHY | BPHL, PDE12, UROD | PDE5A 14/4885KDM4E 4291/4885RECQL 878/4885 |
| US-20090318478-A1 | QUINAZOLINE DERIVATIVES | PDE9A, PDE3A, PDE5A | PDE5A 3/4885KDM4E 2869/4885RECQL 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.